project

PANXEON

Blood-based liquid biopsy for pancreatic ductal adenocarcinoma that combines circulating microRNAs, exosomal microRNAs and the CA19-9 protein into a single machine-learning risk score. Also reported as PAXEON.

Known aliases

PAXEON

Relationships

No evidence-backed relationships are recorded.

Current clusters

science2 publishers

A three-marker blood test flagged 87% of stage 1 and 2 pancreatic cancers in 1,800 patients

A City of Hope team reports catching stage 1 and 2 pancreatic cancer from a three-marker blood score. The trial does not settle what a positive means in the high-risk groups a screening programme would enrol first.

Publishers:discovermagazine.comscientificamerican.com

Reality

Evidence57
Adoption8
Hype gap+33
Incentives63
Confidence61